We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Akebia’s Vadadustat Receives FDA Complete Response Letter
Akebia’s Vadadustat Receives FDA Complete Response Letter
Akebia Therapeutics will have to conduct a new clinical trial if it wants to move its kidney disease drug vadadustat forward, the FDA said in a Complete Response Letter (CRL) denying approval for the investigational drug.